COVID-19 Resource Center
1.866.648.2767

COVID-19 Resource Center

Resources

TRHC Precision Research and Development Institute COVID-19 Resources

Potential Treatment Options for COVID-19 Medication Chart – See chart

NIH Registered Clinical Trials
Simulation of Risk of Adverse Drug Events Associated with the Initiation of Drugs Repurposed for the Treatment of COVID-19 in Frail Elderly Adults With Polypharmacy – Read more

Simulation of Risk of Adverse Drug Events Associated With the Initiation of Drugs Repurposed for the Treatment of COVID-19 in Adults With Polypharmacy Using Data From Large Medicare and Commercially Insured Populations – Read more 

COVID-19 Resources for PACE

TRHC’s CareKinesis® COVID-19 resource for PACE page includes information on the coronavirus and COVID-19, including test kits, BioIntelliSense BioStickers™, potential treatment options, webinars, and potential COVID-19 treatment options, and clinical studies.

Pharmacist COVID-19 Resources

TRHC’s PrescribeWellness™ coronavirus webpage includes quick links for pharmacies, including an online order form for COVID-19 test kits, as well as timely collated updates generated from venerable sources such as the Centers for Disease Control and Prevention (CDC) and the World Health Organization (WHO).

Webinar: Important Medication Safety Considerations for COVID-19 Treatment

Access TRHC’s webinar about the risks associated with COVID-19 treatment, particularly with vulnerable individuals who have several chronic diseases and take multiple medications. View recorded webinar >

COVID-19 Related Press Releases

Results of Tabula Rasa HealthCare’s First Simulated Clinical Study on Proposed COVID-19 Treatments and Therapies is Published

  MOORESTOWN, NJ, (August 12, 2020) – Tabula Rasa HealthCare, Inc® (TRHC) (NASDAQ: TRHC), a healthcare technology company advancing the field of medication safety, announces TRHC’s Precision Pharmacotherapy Research and Development Institute (PPRDI) published the research article, “Risk of Adverse Drug Events Following the Virtual Addition of COVID-19 Repurposed Drugs to Drug Regimens of Frail Older Adults with Polypharmacy”, in the August 10, 2020, online edition of the Journal of Clinical Medicine. The article is... Read More

Regence and TRHC Partner on COVID-19 Virtual Clinical Trial to Assess Proposed Treatment Risks

Moorestown, NJ, June 9, 2020 – Regence and Tabula Rasa HealthCare® (NASDAQ: TRHC) announced today that the companies have partnered on a virtual clinical trial to assess the risk of adverse drug events (ADEs) associated with drugs repurposed for the treatment of COVID-19. The trial examines de-identified medical information for approximately 500,000 Regence health plan members across multiple lines of business. Regence is a family of health plans in Oregon, Idaho, Utah and select counties... Read More

TRHC Fills the Information Gap on COVID-19 Proposed Therapies with a New Digital Resource

Moorestown, NJ, May 19, 2020 – Tabula Rasa HealthCare® Corporation (NASDAQ: TRHC), a healthcare technology company advancing the field of medication safety, today published on the web the TRHC COVID-19 Treatment and Therapy Digital Resource. Developed by TRHC’s Precision Pharmacotherapy Research & Development Institute, the resource provides a comprehensive analysis and clinical reviews of potential treatments and therapies for COVID-19. “There are knowledge gaps surrounding the proposed treatments for COVID-19,” said TRHC Chairman and CEO... Read More

TRHC Launches First Large Simulation Study to Assess Adverse Drug Events with proposed COVID-19 Treatments

Moorestown, NJ, April 29, 2020 – Tabula Rasa HealthCare Corporation® (NASDAQ: TRHC), a healthcare technology company advancing the field of medication safety, announced today it is running a clinical study assessing the risk of adverse drug events (ADEs) associated with drugs repurposed for the treatment of COVID-19 in older adults on multiple medications. “This study showcases the depth and breadth of our clinical research capabilities,” said TRHC Chairman and CEO Calvin H. Knowlton, PhD. “The... Read More

Tabula Rasa HealthCare and Strategic Solutions Network Partner on a Free COVID-19 Medication Safety Webinar

MOORESTOWN, N.J., April 23, 2020 (GLOBE NEWSWIRE) — Tabula Rasa HealthCare Corporation® (NASDAQ: TRHC), a healthcare technology company advancing the field of medication safety, and Strategic Solutions Network, a privately-held business-to-business conference company, will present a free webinar entitled Important Medication Safety Considerations for COVID-19 Treatment on Thursday, May 7, 2020 at 1 p.m. EDT. Participants may register here. The webinar will discuss the importance of understanding the risks associated with COVID-19 treatment risks, particularly... Read More

Tabula Rasa HealthCare® and CQuentia® Expand Partnership with COVID-19 Test Kit Distribution Agreement

MOORESTOWN, N.J., April 16, 2020 — Tabula Rasa HealthCare®, Inc. (TRHC) (NASDAQ: TRHC), a healthcare technology company advancing the field of medication safety, today announced an expanded laboratory services agreement with CQuentia, a comprehensive analytics platform and molecular laboratory for personalized medicine. The agreement provides TRHC with access to COVID-19 (SARS-CoV-2 RNA) testing kits for distribution to Programs of All-Inclusive Care for the Elderly (PACE) through TRHC’s CareKinesis Pharmacy. Through its relationship with CQuentia, TRHC... Read More